BioCentury | Nov 11, 2013
Clinical News

C1qScreen regulatory update

...diagnostic procedures and launched it in Europe. The product is a solid-phase assay that uses One Lambda's...
...beads to distinguish complement binding donor-specific antibodies (DSAs) from non-complement binding DSAs. Thermo Fisher acquired One Lambda...
BioCentury | Jul 23, 2012
Company News

One Lambda, Thermo Fisher deal

...Fisher will acquire transplant diagnostics company One Lambda for $925 million in cash. Thermo Fisher said One Lambda's...
...human leukocyte antigen (HLA) typing and antibody detection tests will complement its immunosuppressant monitoring assays. One Lambda...
...Fisher, while Wilmer Cutler Pickering Hale and Dorr is legal counsel. Perella Weinberg is advising One Lambda...
BioCentury | Jul 17, 2012
Company News

Thermo Fisher to acquire One Lambda

...transplant diagnostics company One Lambda Inc. (Canoga Park, Calif.) for $925 million in cash. Thermo Fisher said One Lambda's...
...leukocyte antigen (HLA) typing and antibody detection tests will complement Thermo Fisher's immunosuppressant monitoring assays. One Lambda...
...Fisher, while Wilmer Cutler Pickering Hale and Dorr is legal counsel. Perella Weinberg is advising One Lambda...
BioCentury | Dec 13, 2010
Company News

Luminex, One Lambda Inc. deal

...The partners renewed a 2000 deal giving One Lambda rights to use Luminex's xMAP technology to develop...
...SSO to identify HLA alleles (see BioCentury, Nov. 13, 2000). Luminex Corp. (NASDAQ:LMNX), Austin, Texas One Lambda Inc....
BioCentury | Nov 13, 2000
Company News

Luminex, One Lambda Inc. deal

...received an upfront payment and will be eligible for royalties. Luminex Corp. (LMNX), Austin, Texas One Lambda Inc....
BioCentury | Nov 10, 2000
Company News

One Lambda and Luminex partner on tissue typing

The companies announced a collaboration to use LMNX's LabMAP technology to develop HLA ( human leukocyte antigen )-based applications, including tissue typing for transplantation purposes. Lambda received nonexclusive worldwide rights to develop and distribute reagents and...
Items per page:
1 - 6 of 6
BioCentury | Nov 11, 2013
Clinical News

C1qScreen regulatory update

...diagnostic procedures and launched it in Europe. The product is a solid-phase assay that uses One Lambda's...
...beads to distinguish complement binding donor-specific antibodies (DSAs) from non-complement binding DSAs. Thermo Fisher acquired One Lambda...
BioCentury | Jul 23, 2012
Company News

One Lambda, Thermo Fisher deal

...Fisher will acquire transplant diagnostics company One Lambda for $925 million in cash. Thermo Fisher said One Lambda's...
...human leukocyte antigen (HLA) typing and antibody detection tests will complement its immunosuppressant monitoring assays. One Lambda...
...Fisher, while Wilmer Cutler Pickering Hale and Dorr is legal counsel. Perella Weinberg is advising One Lambda...
BioCentury | Jul 17, 2012
Company News

Thermo Fisher to acquire One Lambda

...transplant diagnostics company One Lambda Inc. (Canoga Park, Calif.) for $925 million in cash. Thermo Fisher said One Lambda's...
...leukocyte antigen (HLA) typing and antibody detection tests will complement Thermo Fisher's immunosuppressant monitoring assays. One Lambda...
...Fisher, while Wilmer Cutler Pickering Hale and Dorr is legal counsel. Perella Weinberg is advising One Lambda...
BioCentury | Dec 13, 2010
Company News

Luminex, One Lambda Inc. deal

...The partners renewed a 2000 deal giving One Lambda rights to use Luminex's xMAP technology to develop...
...SSO to identify HLA alleles (see BioCentury, Nov. 13, 2000). Luminex Corp. (NASDAQ:LMNX), Austin, Texas One Lambda Inc....
BioCentury | Nov 13, 2000
Company News

Luminex, One Lambda Inc. deal

...received an upfront payment and will be eligible for royalties. Luminex Corp. (LMNX), Austin, Texas One Lambda Inc....
BioCentury | Nov 10, 2000
Company News

One Lambda and Luminex partner on tissue typing

The companies announced a collaboration to use LMNX's LabMAP technology to develop HLA ( human leukocyte antigen )-based applications, including tissue typing for transplantation purposes. Lambda received nonexclusive worldwide rights to develop and distribute reagents and...
Items per page:
1 - 6 of 6